Anti-bronylete protection reimbursed for all children at risk

VR, a virus that continues to worry families

Each autumn winter, pediatric services are preparing for the bronchiolite epidemic. This respiratory infection, often benign, can however evolve towards serious forms in the most fragile children: premature, babies with cardiac or lung pathologies or immunocompromed children.

In France, it is estimated that one in three infants is influenced by bronchiolitis during his first year of life. The majority is based on it with a simple medical follow -up, but some require hospitalization, sometimes in intensive care.

Le Beyfortus, a reinforced prevention tool

THE Nirsévimab (Beyfortus®) It is a monoclonal antibody developed by Sanofi and Astrazeneca. It is not proper vaccine, but a unique injection that offers immediate and lasting protection against VR, covering the entire winter season.

Until now, the care mainly concerned children during their first season at risk. From now on, the extension validated by the Government provides that the treatment will be Also reimbursed for children up to 24 months who remain vulnerable during their second winter.

Concrete, this means that a child born prematurely or that suffering from chronic pathologies will be able to benefit from a new injection the next winter, without any cost for his parents.

What changes to families

For parents, this decision lightens a financial and medical weight. Beyfortus, whose cost could reach several hundred euros, will now be Completely covered by health insurance In the situations defined by high health authority.

This measure should also contribute Hospital Unogggs During the winter, reducing the number of serious cases of bronchiolitis that require hospitalization.

An extensive public health strategy

The introduction of Beyfortus in children’s career is part of a wider policy of preventing respiratory infections. Complete classic recommendations: washing of frequent hands, limitation of contacts with registered people, ventilation of parts and wearing the mask for adults with symptoms.

However, the health authorities insist: Nirsévimab is not intended for all children. The pediatricians will determine on the basis of the basic case such as children are eligible, depending on their age, their state of health and associated risks.

Protection that reassures before winter

For the families concerned, this announcement is timely, at the dawn of the winter virus season. While each parent fears the whistle cough and the breathing difficulties characteristic of bronchiolitis, knowing that fragile children can benefit from the reimbursed protection provides a breath of relief.

It remains to take care of the good organization of the campaign, so that all suitable children can receive Beyforus in time. Another step towards a better prevention of respiratory infections in the little ones.

Source: Madmoizelle